Navigating Anti-Neuronal Antibody Testing for Neuropsychiatric Disorders
Autoimmune Brain Panel™ in clinical practice
For a subset of patients, chronic anxiety, OCD, mood changes, and behavioral symptoms may reflect an underlying immune-mediated process affecting the nervous system — often times following an infection — rather than a primary psychiatric condition alone. When symptoms persist despite appropriate psychotropic treatment, clinicians may consider whether an autoimmune or neuroinflammatory contributor could be involved.
HAVE QUESTIONS ABOUT TESTING?
PRESENTER: Craig Shimasaki, PhD, MBA, President & CEO, Moleculera Biosciences
DATE: Friday, November 6th
TIME: 12pm CT
ABOUT WEBINAR
This 45-minute discussion will provide a brief overview of testing with the Autoimmune Brain Panel™ (formerly the Cunningham Panel™) and its potential role in evaluating patients with neuropsychiatric symptoms that may have an autoimmune component.
There were will ample time for Q&A, including discussion of your patient cases and questions about testing.
We'll review:
- The underlying science of immune-mediated neuropsychiatric conditions.
- Key clinical indicators: Identifying candidates for Autoimmune Brain Panel™ testing.
- How to evaluate and apply test results.
- Review real-world patient cases ─ including Panel results and treatment outcomes.
- Live Q&A